Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

PHASE4TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

September 28, 2023

Study Completion Date

September 28, 2023

Conditions
ALK or ROS1-positive NSCLC
Interventions
DRUG

Crizotinib

receive crizotinib orally

Trial Locations (14)

100142

Beijing Cancer Hospital, Internal Department, Beijing

130000

Jilin Province Cancer Hospital, Changchun

130012

Jilin Provincial Cancer Hospital, Changchun

200030

Shanghai Chest Hospital, Shanghai

200032

Zhongshan Hospital Fudan University, Shanghai

210002

Eastern Theater General Hospital ,QinHuai District Medical Area, Nanjing

310003

Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

350014

Fujian Province Oncology Hospital, Fuzhou

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

510145

The First Affiliated Hospital of Guangzhou Medical University, Liwan District,Guangzhou

610041

Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu

Sichuan Province Cancer Hospital, Chengdu

West China Hospital of Sichuan University, Chengdu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03672643 - Long Term Safety Observation of Crizotinib in Chinese NSCLC Population | Biotech Hunter | Biotech Hunter